Brokerages Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) PT at $129.56

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have earned a consensus recommendation of “Moderate Buy” from the nineteen research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $129.5625.

BNTX has been the topic of a number of research reports. Raymond James Financial reaffirmed an “outperform” rating on shares of BioNTech in a research note on Tuesday, March 10th. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. The Goldman Sachs Group reaffirmed a “buy” rating on shares of BioNTech in a research report on Wednesday, March 11th. Bank of America reaffirmed a “buy” rating and issued a $128.00 target price on shares of BioNTech in a research note on Tuesday, March 10th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of BioNTech in a report on Tuesday, March 17th.

Insider Activity

In related news, COO Sierk Poetting sold 50,000 shares of BioNTech stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total value of $5,528,000.00. Following the sale, the chief operating officer owned 399,387 shares of the company’s stock, valued at approximately $44,156,226.72. This trade represents a 11.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.20% of the company’s stock.

Hedge Funds Weigh In On BioNTech

Large investors have recently bought and sold shares of the company. Bank of America Corp DE grew its stake in shares of BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after acquiring an additional 166,432 shares in the last quarter. Amundi lifted its position in shares of BioNTech by 24.5% in the first quarter. Amundi now owns 129,513 shares of the company’s stock worth $11,511,000 after purchasing an additional 25,506 shares in the last quarter. Royal Bank of Canada lifted its position in shares of BioNTech by 15.5% in the first quarter. Royal Bank of Canada now owns 46,991 shares of the company’s stock worth $4,177,000 after purchasing an additional 6,308 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in BioNTech during the first quarter worth $499,000. Finally, Sei Investments Co. bought a new position in BioNTech in the first quarter valued at $220,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Trading Up 0.9%

NASDAQ BNTX opened at $93.92 on Thursday. The firm has a market cap of $23.75 billion, a P/E ratio of -15.97 and a beta of 1.32. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.80 and a quick ratio of 8.74. The stock’s 50-day moving average is $93.38 and its 200-day moving average is $97.88. BioNTech has a one year low of $79.52 and a one year high of $124.00.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) earnings per share (EPS) for the quarter. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. The business had revenue of $1.06 billion during the quarter. Sell-side analysts anticipate that BioNTech will post -5.67 earnings per share for the current fiscal year.

BioNTech declared that its board has authorized a stock repurchase program on Thursday, May 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to repurchase up to 4.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.